Hemispherian begins Phase I/IIa trial of GLIX1 for GBM

​Hemispherian has initiated a first-in-human Phase I/IIa trial of its oral small molecule, GLIX1, in patients with recurrent and progressive GBM and other high-grade gliomas.

The post Hemispherian begins Phase I/IIa trial of GLIX1 for GBM appeared first on Hospital Management.

 

Back to the Featured Stories

Featured Stories

MHRA secures $4.8m to expand AI medical device programme
Jeito Capital secures over $1.2bn for new biopharma investments
J&J advances PFA portfolio with Varipulse Pro launch in Europe
First patient dosed in CatalYm’s Phase IIb visugromab trial
Halozyme and Vertex sign deal for Hypercon technology

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.

Contact Us